MedTrace Logo

Clinical Trial of SARS-CoV-2 mRNA Vaccine in China

NCT05364047 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2022-12-05

No results posted yet for this study

Summary

This study is a phase I clinical trial. The investigators intent to evaluate the safety, tolerability and preliminary immunogenicity of SARS-CoV-2 mRNA vaccine (LVRNA009) in Chinese people aged 18 years and over.

Conditions

Interventions

BIOLOGICAL

Low-dose of LVRNA009

25μg/person

BIOLOGICAL

Middle-dose of LVRNA009

50μg/person

BIOLOGICAL

High-dose of LVRNA009

100μg/person

OTHER

Placebo

0.5ml/person

Sponsors & Collaborators

  • Shulan (Hangzhou) Hospital

    collaborator OTHER

  • Yuncheng Central Hospital

    collaborator OTHER

  • AIM Vaccine Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Lanjuan Li · Shulan (Hangzhou) Hospital

  • Guiling Chen · Shulan (Hangzhou) Hospital

  • Fengli Zhao · Yuncheng Central Hospital

  • Jinlian Bi · Xiangya Boai Rehabilitation Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-31
Primary Completion
2022-10-14
Completion
2023-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05364047 on ClinicalTrials.gov